Claude

The Full Story

Religare Enterprises has undergone one of the most dramatic corporate transformations in Indian financial services over the past decade. The narrative arc runs from an ambitious diversified financial conglomerate built by the Singh brothers, through a devastating fraud-driven collapse (2017-2020), a protracted stabilization under professional management led by Dr. Rashmi Saluja (2018-2024), a bitter corporate control battle, and finally a new chapter under the Burman Group (Dabur promoters) starting February 2025. Management credibility has been reset almost entirely – the old story is dead, and the new one is still being written.

The Narrative Arc

The pre-2018 narrative was straightforward: Religare was an "integrated financial services platform" serving 1.5 million clients with lending as its largest vertical (56% of revenue in Q1 FY16). RFL had a lending book of Rs 139 Bn with AA- credit ratings. Then the Singh brothers – Malvinder and Shivinder, heirs to the Ranbaxy fortune – were exposed for systematically siphoning Rs 2,037 Cr through a Corporate Loan Book (CLB) using 19 shell companies over eight years.

The scale of destruction was staggering. Revenue fell from Rs 49 Bn (FY2016) to Rs 24 Bn (FY2019). Operating income turned negative. The lending business, which was the core of Religare, went from generating Rs 6 Bn in quarterly income to zero. RBI imposed a Corrective Action Plan on RFL in January 2018 that prohibited credit/investment expansion and dividend payments. All lenders classified RFL as fraud in 2020.

Dr. Rashmi Saluja took over as Executive Chairperson in December 2018 and spent the next six years on stabilization: settling RFL's debt through a One-Time Settlement, growing Care Health Insurance from a small SAHI player into the industry's second-largest, and keeping the broking business operational. But her tenure ended controversially – SEBI issued an order in June 2024 citing governance violations, IRDAI directed Care Health to buy back ESOPs issued to her, and shareholders voted against her re-appointment at the February 2025 AGM, after which her role ceased.

What Management Emphasized – and Then Stopped Emphasizing

What was dropped: The pre-crisis story centered on lending growth and being a diversified financial conglomerate. Asset Management (Religare Invesco AMC) was sold. The Aegon Religare life insurance JV was exited. The "1.5 million clients across 1,644 locations" narrative quietly disappeared after 2018. The lending business – once 56% of consolidated revenue – became a pure resolution story for seven years.

What replaced it: Health insurance became the anchor. Care Health's GWP grew from under Rs 2,000 Cr pre-FY20 to Rs 9,200 Cr in FY25. By FY2025, insurance comprised the vast majority of consolidated revenue. Every annual report from FY2021 onwards led with Care Health metrics. The "revival" narrative dominated the Saluja era – every chairperson's letter referenced "challenging times" and "building a strong integrated financial services group."

What emerged in 2025-26: The Burman era introduced three new themes: "sustainable profitable growth anchored in prudence," "value unlock through demerger," and "strong promoter backing." The Nov 2025 earnings call – the first in years – explicitly stated: "We chose reform over rhetoric, and we chose to fix what was broken."

Risk Evolution

The risk profile has fundamentally shifted. The original existential risks – fraud, lender defaults, regulatory shutdown – have been substantially resolved. RFL completed its OTS, became debt-free, had CAP removed (July 2025), and had fraud tags removed by all lenders including through Delhi High Court orders.

However, new risks have emerged. The corporate governance risk peaked again in FY2024 when SEBI issued its interim order against REL and all directors for violating SAST Regulations (failing to facilitate the Burman open offer). The Daiichi litigation remains a persistent risk – a status quo order on the "Religare" brand itself is outstanding, and Elive Infotech has sought Rs 323 Cr from REL for unauthorized brand usage.

The HoldCo discount risk persists: REL trades at a significant discount to the sum of its parts, principally the 63.2% stake in Care Health Insurance. The Feb 2026 demerger announcement directly addresses this, but its completion is 15-18 months away.

How They Handled Bad News

The Fraud Discovery (2018): Management handled this by fully provisioning the corporate loan book (Rs 81,468 Lakhs), filing criminal complaints against the erstwhile promoters, and cooperating with ED/SFIO investigations. The FY2018 annual report admitted the loss was due to "one time provision of Rs 1,017.85 crore taken by Religare Finvest Limited on its corporate loan book." This was honest but took years to fully surface.

The SEBI Order (June 2024): SEBI's interim order alleged REL violated SAST Regulations by failing to facilitate the Burman open offer. Management appealed to SAT, then complied with directions to file RBI applications. In the FY2025 annual report, REL disclosed it withdrew the SAT appeal and filed a fresh application with SEBI requesting action against the erstwhile Executive Chairperson.

The Saluja Departure (Feb 2025): This was the most contentious event. Shareholders voted against Dr. Saluja's re-appointment at the AGM. She filed multiple lawsuits challenging her removal. IRDAI ordered Care Health to buy back ESOPs issued to her. REL's FY2025 report explicitly disclosed that the company asked SEBI to "take appropriate action against Noticee No. 2 i.e. erstwhile Executive Chairperson." The new management drew a clear line.

Q3 FY26 Operating Loss (Dec 2025): A consolidated PBT loss of Rs 103 Cr was attributed to "onetime employee benefit provisions related to past service liabilities" from new labor code implementation. Management flagged this upfront and the handling was transparent.

Guidance Track Record

The guidance track record splits cleanly into two categories. The backward-looking cleanup promises – OTS, debt-free status, fraud tag removal, CAP lifting – were all delivered, though they took longer than originally hoped. The forward-looking growth promises – demerger, RFL restart, housing finance scale-up, broking improvement – are all in their earliest stages with zero execution evidence. The Rs 1,500 Cr preferential issue has only seen Rs 410 Cr received through Q3 FY26.

What the Story Is Now

The current story is a holding company restructuring play backed by the Burman Group (Dabur promoters). The core thesis rests on four pillars:

What has been de-risked: The Singh brothers' fraud has been fully provisioned and legally pursued. RFL's lender debt is settled. The CAP and fraud tags are removed. A credible promoter group is now in control with board representation. The corporate governance battle (Saluja vs. Burman) appears resolved.

What remains stretched: The stock trades at 73x earnings for a holding company whose principal asset (Care Health, 63.2% stake) is not yet independently valued in the public market. The "value unlock" thesis requires the demerger to be completed (15-18 months), the Care Health holding to be re-rated, and RFL to successfully restart lending – none of which have happened yet.

The broking business has declining active clients (14% activation vs. industry 21%) and single-digit ROE. Housing finance has Rs 241 Cr AUM. RFL has Rs 480 Cr cash but no active lending operations.

What to believe: Care Health Insurance is the one proven asset. With Rs 9,200+ Cr GWP, 22% SAHI market share, consistent profitability since FY19, and a combined ratio around 100%, it is a legitimate franchise. The 33% GWP CAGR over three years on a full premium basis is real. The Burman Group's track record building Dabur provides credibility for institution building.

What to discount: Forward growth projections for RFL, housing finance, and broking are aspirational with no execution track record. The Rs 1,500 Cr capital raise is only 27% collected. The demerger timeline of 15-18 months requires multiple regulatory approvals. Daiichi litigation and brand ownership risk remain unresolved. The new management team is still being assembled – the broking MD joined in February 2026, and the CFO noted "in next couple of quarters, you will see many more experienced business leaders joining."